BioForm Medical Acquires Facial Aesthetic Nerve Ablation ...(ions with a toxin stated Steven Basta CE...),Health

Date:4/30/2008

ions with a toxin," stated Steven Basta, CEO of BioForm Medical. "We believe that the synergy of this product with our Radiesse dermal filler will be terrific. We have a differentiated, long-lasting filler, and in the coming years we hope to offer physicians a new treatment option for frown lines. This is part of our commitment to partnering with physicians to offer them improved aesthetic treatment options that can grow their practices. This device could appeal to many of the same physicians who select Radiesse dermal filler for their patients, and will leverage our existing sales and marketing organization."

In the acquisition of ACI, BioForm Medical will hire several of ACI's employees, and retain others as consultants to maintain continuity of this program and to accelerate future product development and commercialization activities. In addition to the up-front consideration, BioForm Medical will pay a single-digit royalty to ACI. The Company anticipates that significant positive revenue impact of this acquisition is not likely until it obtains clearance for the product for aesthetic applications, anticipated to occur in calendar year 2009.

BioForm Medical will discuss this transaction further on Thursday, May 1, 2008, when it reports its financial results for the quarter ended March 31, 2008, and holds a conference call with investors at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time).

About the ACI Device & the Market for Treatment of Frown Lines:

The ACI device provides a minimally invasive technique for creating a focal lesion inhibiting the function of the target nerve. The product is comprised of a RF energy generator box, approximately the size of a small monitor, a sterile handheld probe and a foot pedal to activate energy delivery. The probe has two functions -- stimulating the nerve to identify the proper location for treatment, and delivering the heat energy in a measured dose to reduce activity of the targeted nerve. The m
'/>"/>

SOURCE BioForm Medical, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related medicine news :

1. BioForm Medical to Announce Financial Results For Quarter Ended March 31, 2008, Third Quarter of Fiscal 2008, and Host Conference Call and Webcast on May 1, 2008
2. BioForm Announces Financial Results for Quarter Ended December 31, 2007, Second Quarter of Fiscal 2008
3. BioForm to Announce First Quarter Fiscal 2008 Financial Results and Host Conference Call and Webcast on December 13, 2007
4. ATS Medical Announces First Frontiers in Cryoablation Symposium
5. Medical journal calls upon Barack Obama to do much more
6. ACP hosts largest medical education meeting for general and subspecialty internists
7. Flashpoint Medica Named Agency of Year by Medical Advertising News
8. Virginia Judge Rules Medical Device Pioneer Committed Malpractice
9. Digirad Corporation and University of Chicago Medical Center Sign Letter of Agreement
10. PSI Corp. Announces Additional Hospitals and Medical Office Buildings to Utilize Its Digital Signage Network
11. Labopharm Appoints Dr. Claire Brulle as Senior Vice-President and Chief Medical Officer